Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares fell 5% on Monday . The stock traded as low as $4.55 and last traded at $4.56. 47,927 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 1,351,573 shares. The stock had previously closed at $4.80.
Autolus Therapeutics Stock Down 5.8 %
The company has a 50-day moving average of $3.94 and a two-hundred day moving average of $4.11. The company has a market capitalization of $1.20 billion, a PE ratio of -3.76 and a beta of 2.04. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Sell-side analysts anticipate that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Autolus Therapeutics
A number of hedge funds have recently made changes to their positions in AUTL. Privium Fund Management B.V. boosted its stake in Autolus Therapeutics by 43.2% in the 1st quarter. Privium Fund Management B.V. now owns 50,058 shares of the company's stock worth $319,000 after purchasing an additional 15,091 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company's stock valued at $736,000 after purchasing an additional 111,131 shares during the last quarter. Capstone Investment Advisors LLC increased its holdings in shares of Autolus Therapeutics by 58.7% in the first quarter. Capstone Investment Advisors LLC now owns 79,374 shares of the company's stock worth $506,000 after purchasing an additional 29,374 shares during the last quarter. SG Americas Securities LLC bought a new position in Autolus Therapeutics during the first quarter valued at approximately $127,000. Finally, EntryPoint Capital LLC grew its holdings in Autolus Therapeutics by 113.6% during the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company's stock valued at $137,000 after buying an additional 11,456 shares in the last quarter. Institutional investors own 72.83% of the company's stock.
Autolus Therapeutics Company Profile
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Articles
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
